As with other patients receiving immunosuppressants, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies particularly of the skin. Because of the danger of oversuppression of the immune system which can increase susceptibility to infection, treatment with combined immunosuppressives should be used with caution. Hypertension is a common adverse effect of Seegraf therapy. Mild or moderate hypertension is more frequently reported than severe hypertension. Antihypertensive therapy may be required; the control of blood pressure can be accomplished with any of the common antihypertensive agents.
Use in pregnancy & lactation: Seegraf should be recommended only if the potential benefit justifies the potential risk to the foetus.
Since Seegraf is excreted in human milk, nursing should be avoided.
Use in children: Pediatric patients generally required higher doses of Seegraf to maintain blood trough concentrations of tacrolimus similar to adult patients.